



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

SU11652

Cat. No.:	HY-112452
CAS No.:	326914-10-7
Molecular Formula:	C ₂₂ H ₂₇ ClN ₄ O ₂
Molecular Weight:	414.93
Target:	VEGFR; FGFR; PDGFR; c-Kit; Apoptosis
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 10 mg/mL (24.10 mM; ultrasonic and warming and heat to 60°C)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.4100 mL	12.0502 mL	24.1005 mL
	5 mM		0.4820 mL	2.4100 mL	4.8201 mL
	10 mM		0.2410 mL	1.2050 mL	2.4100 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

SU11652 is a potent receptor tyrosine kinase (RTK) inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including VEGFR, FGFR, PDGFR, and Kit. SU11652 can be used for spontaneous cancers expressing Kit mutations research^[1].

IC₅₀ & Target

IC₅₀: 0.01 μM (PDGFR), 0.03 μM (Flk-1), 0.05 μM (c-kit)^[1]

In Vitro

SU11652 (0-1 μM, 0-72 h) inhibits the growth of mast cell lines expressing mutant Kit^[1].
 SU11652 (0-1 μM, 0-72 h) induces cell cycle arrest followed by apoptosis in cell lines expressing mutant Kit^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Liao AT, et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood. 2002;100(2):585-593.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA